Neurology
Clearing Amyloid Is Not the Same as Saving Cognition
Real-world lecanemab monitoring found that the blood proteins associated with amyloid clearance were largely different from those associated with cognitive decline. Alzheimer’s treatment response is more complicated than one biomarker moving in the right direction.
ALS Needs Proof, Not Just Another Biomarker
For Pompe Infants, Time Is the Comparator
Alzheimer’s Trials Still Measure Too Little, Too Late
Eight Patients Cannot Solve Alzheimer’s. They Can Tell Us What the Next Trial Must Prove.
The ICU Has a New Signal. It Is Not a Verdict.
The Trial Has Started. Now the System Has to Find the Children.
Sleep is now cardiovascular prevention. Health systems still treat it like lifestyle advice
ADHD Does Not Stop Being ADHD When Anxiety Walks Into the Room
Dementia prevention has a cardiometabolic blind spot
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
Diseases in Neurology
Explore disease data and country profiles on the IPM Alliance platform.
Explore diseases